You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Last Updated: January 22, 2021

DrugPatentWatch Database Preview

Patent: 9,358,232

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,358,232

Title:	Methods for treating cancer using TOR kinase inhibitor combination therapy
Abstract:	Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phen- yl)acrylamide to a patient having a cancer.
Inventor(s):	Hege; Kristen Mae (Burlingame, CA), Chopra; Rajesh (Summit, NJ)
Assignee:	Signal Pharmaceuticals, LLC (San Diego, CA)
Application Number:	14/254,010
Patent Claims:	see list of patent claims

Details for Patent 9,358,232

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech Inc	RITUXAN HYCELA	rituximab; hyaluronidase (human recombinant)	SOLUTION;SUBCUTANEOUS	761064	002	2017-06-22	Start Trial	Signal Pharmaceuticals, LLC (San Diego, CA)	2033-04-17	RX	Orphan	search
Genentech Inc	RITUXAN HYCELA	rituximab; hyaluronidase (human recombinant)	SOLUTION;SUBCUTANEOUS	761064	001	2017-06-22	Start Trial	Signal Pharmaceuticals, LLC (San Diego, CA)	2033-04-17	RX	Orphan	search
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	002	1997-11-26	Start Trial	Signal Pharmaceuticals, LLC (San Diego, CA)	2033-04-17	RX		search
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	001	1997-11-26	Start Trial	Signal Pharmaceuticals, LLC (San Diego, CA)	2033-04-17	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patent Family for US Patent 9,358,232

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2014172430	Start Trial
United States of America	2014314751	Start Trial
Taiwan	201521725	Start Trial
Mexico	2015014455	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca

Express Scripts

Moodys

McKesson

McKinsey

Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.